Protocols for multi‐site trials using hyperpolarized ¹²⁹Xe MRI for imaging of ventilation, alveolar‐airspace size, and gas exchange: A position paper from the ¹²⁹Xe MRI clinical trials consortium

Abstract

Hyperpolarized (HP) ¹²⁹ Xe MRI uniquely images pulmonary ventilation, gas exchange, and terminal airway morphology rapidly and safely, providing novel information not possible using conventional imaging modalities or pulmonary function tests. As such, there is mounting interest in expanding the use of biomarkers derived from HP ¹²⁹ Xe MRI as outcome measures in multi-site clinical trials across a range of pulmonary disorders. Until recently, HP ¹²⁹ Xe MRI techniques have been developed largely independently at a limited number of academic centers, without harmonizing acquisition strategies. To promote uniformity and adoption of HP ¹²⁹ Xe MRI more widely in translational research, multi-site trials, and ultimately clinical practice, this position paper from the ¹²⁹ Xe MRI Clinical Trials Consortium (https://cpir.cchmc.org/XeMRICTC) recommends standard protocols to harmonize methods for image acquisition in HP ¹²⁹ Xe MRI. Recommendations are described for the most common HP gas MRI techniques-calibration, ventilation, alveolar-airspace size, and gas exchange-across MRI scanner manufacturers most used for this application. Moreover, recommendations are described for ¹²⁹ Xe dose volumes and breath-hold standardization to further foster consistency of imaging studies. The intention is that sites with HP ¹²⁹ Xe MRI capabilities can readily implement these methods to obtain consistent high-quality images that provide regional insight into lung structure and function. While this document represents consensus at a snapshot in time, a roadmap for technical developments is provided that will further increase image quality and efficiency. These standardized dosing and imaging protocols will facilitate the wider adoption of HP ¹²⁹ Xe MRI for multi-site pulmonary research.